Figure 13.

(A) Quantitative analysis of integrin α_vβ₃ density for six different human cancer tissues (colon cancer, pancreatic cancer, lung adenocarcinoma, squamous cell lung cancer, gastric cancer, and esophageal cancer) stained with FITC-Galacto-RGD₂ (green). Integrin α_vβ₃ density on tumor cells and neovasculature is represented by the percentage of green area over the total area in each tumor slice. (B) Quantitative analysis of integrin β₃ density for six human cancer tissues (colon cancer, pancreatic cancer, lung adenocarcinoma, squamous cell lung cancer, gastric cancer, and esophageal cancer) stained with rabbit anti-human integrin β₃ antibody detected with the TR-conjugated goat anti-rat antibody (red). Integrin α_vβ₃ density on tumor cells and neovasculature is represented by the percentage of red area over the total area in each slice of tumor tissue. (C) (average data) and (D) (single data): Linear relationship between the relative integrin α_vβ₃ expression levels (fluorescence density) determined with FITC-Galacto-RGD₂ and those obtained with rabbit anti-human integrin β₃ antibody in six human tumors (colon cancer, pancreatic cancer, lung adenocarcinoma, squamous cell lung cancer, gastric cancer, and esophageal cancer). Each data point was derived from 15 different areas of the same tumor slice. Experiments were repeated three times independently with very similar results. All values were reported as the average plus/minus standard deviation. †: p < 0.01, significantly different from the colon cancer group; #: p < 0.01, significantly different from the gastric cancer group.